Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease

Gabather has been invited by the Alzheimer's Drug Discovery Foundation (ADDF), USA to submit a research grant application to further investigate the effects of GT-002 in genetic models of Alzheimer's disease. The project application is based on the preliminary data with GT-002 on restoring slow wave oscillations in an Alzheimer's disease model generated during the collaboration between Gabather and Harvard Medical School (HMS).

The project includes the teams from Professor Ksenia Kastanenka (HMS) and Professor Simon Schultz, Imperial Collage London, as well as Gabather as project coordinator. The efficacy of GT-002 to restore dysfunctional brain signals and cognitive functions will be studied.  

Positive results from these studies will strengthen the case for clinical trials of GT-002 in cognitive dysfunction, particularly in Alzheimer's disease patients.

The drug candidate GT-002 is a selective GABAA receptor modulator with the potential to improve the treatment of several common psychiatric disorders. The results from the Phase 1 clinical trials show that the drug candidate is safe and well tolerated and has excellent pharmacokinetic properties in healthy individuals receiving single, as well as repeated doses of GT-002. A clinical study to explore the interaction of GT-002 with GABAA receptors and how it affects human brain activity will be initiated when the medical authority in Portugal has approved the application.